Law report No. GLW-2994 · filed November 16, 2026
Regulation & EnforcementReported case
FDA Classifies Wanbury’s Tanuku API Plant OAI in November 2026
The FDA issued an OAI classification for Wanbury’s Tanuku API plant after a July 2026 inspection. Existing supplies continue, but new U.S. applications will move to Patalganga.
By Priya Raman4 min read885 words
Holding
- The US FDA issued an OAI classification for Tanuku in November 2026 after a July 2026 inspection.
- The July 2026 Form 483 contained six observations.
- Tanuku contributes about 70% of revenue, while direct US revenue is 6%; existing supplies continue.
- Future US ANDAs will use Wanbury’s US FDA-approved Patalganga facility.
- Tanuku received Australia’s TGA GMP certificate on October 30, 2026, valid through December 2028.
By Priya Raman
What did the FDA decide?
In November 2026, the U.S. Food and Drug Administration classified an inspection of Wanbury Limited’s pharmaceutical ingredient plant in Tanuku, Andhra Pradesh, as “Official Action Indicated,” or OAI. The action followed a July 2026 inspection; before that, the site received a Form 483 carrying six observations. The source gives no exact decision day, inspection report or case reference.
The source says OAI status generally requires complete remediation of plant procedures and compliance controls before new product approvals can proceed from the affected site. That is a forward-looking approval constraint, not a reported order stopping current production or shipments.
The source describes US FDA oversight of API plants in India as strict, placing Tanuku’s classification within a broader enforcement setting rather than an isolated plant event.
In plain terms, the FDA has flagged the site for compliance remediation while current supply continues.
Does OAI interrupt existing business?
Current customer orders and ongoing product supplies from Tanuku remain unaffected, according to Wanbury. The company confirmed that “business operations and existing customer product supplies from the unit remain unaffected.” That confirmation addresses continuity; it does not state that the FDA approved the plant or cleared future applications.
SAHI, the source’s market-analysis provider, expects near-term commercial fallout to remain limited because direct US revenue exposure is only 6%. It also views uninterrupted supply as support for baseline cash flow while Wanbury remediates compliance issues with the FDA. Existing products therefore face less immediate disruption than new US launches.
Near-term revenue continuity looks stronger than new-approval continuity.
How large is the exposure?
Tanuku contributes approximately 70% of Wanbury’s total company revenue, while direct US revenue accounts for 6%. On a proportional basis, roughly 70 cents of each revenue dollar is associated with Tanuku, while direct US sales represent six cents. The figures point in different directions: the site is central to the business, yet direct US dependence is small.
The source says non-US export markets and domestic formulation channels remain unhindered, which supports baseline revenue and limits the financial effect of potential US supply delays. It supplies no customer concentration data, product-level margin analysis or quantified earnings sensitivity, so the 70% and 6% figures describe exposure rather than forecast losses.
Tanuku matters more to overall operations than the United States does to direct sales.
Where will future US applications go?
Wanbury will route future US drug applications (ANDAs) through its US FDA-approved Patalganga facility. The company positions Patalganga as an alternative manufacturing platform and a way to insulate its growth pipeline from the Tanuku classification. The source does not say whether the change applies only to new filings or also affects site references in existing applications.
Tanuku-sourced new products can still face delays because OAI typically requires remediation before new approvals proceed from the affected site. Moving new filings to Patalganga does not resolve the agency’s concerns at Tanuku, and the source reports no timetable for that resolution.
New US filings now have a designated alternative site; the FDA’s treatment of Tanuku remains unresolved.
What other developments matter?
On October 30, 2026, Australia’s Therapeutic Goods Administration issued Tanuku a Good Manufacturing Practice Compliance Certificate valid through December 2028. On October 19, 2026, the Andhra Pradesh State Government gave the plant its Best Employer Award. The source presents both developments alongside the FDA action but does not link either recognition to FDA remediation.
The TGA certificate concerns Australian good manufacturing practice, not US approval. The employment award concerns workplace recognition, not regulatory inspection findings. Neither item answers what the six July Form 483 observations required, what corrective actions Wanbury has completed or whether the FDA will schedule a re-inspection.
Neither the Australian certificate nor the state award demonstrates that the US compliance problem has been resolved.
What should investors and practitioners watch?
SAHI assigns a “Neutral” near-term market bias and says the OAI classification may temporarily cap Wanbury’s valuation multiples until regulatory resolution. Its sector view is “Underweight: API Exporters with US Regulatory Exposure,” with a 0-to-3-month horizon. The recommendation is SAHI’s analysis, not a regulatory finding or company forecast.
SAHI identifies two trigger points:
- Receipt of a US FDA re-inspection schedule or Warning Letter status.
- Filing of new ANDAs through the Patalganga facility.
The downside cases are a possible Warning Letter or Import Alert if remediation proves inadequate, and delays in launching new US products sourced from Tanuku. The source identifies neither measure as already issued.
For counsel and compliance teams, the immediate task is to separate supply continuity from approval risk: existing Tanuku orders continue, while new US filing plans move to Patalganga. Teams should track remediation evidence, FDA re-inspection timing and any Warning Letter or Import Alert.
The source does not supply the six Form 483 observations, a remediation plan, an exact OAI date or a company statement beyond the supply-continuity confirmation.
SAHI also omits share-price performance, valuation multiples, earnings estimates and quantified cash-flow forecasts. Its Neutral bias rests on the contrast between continued supplies and limited direct US exposure, not proof that regulatory risk has ended.
The immediate commercial story is continuity; the unresolved regulatory story is what happens next.
via sahi.com (Source)
More from Priya Raman
Show full bio
Staff writer covering companies, deals and strategy in International law and legal practice at Global Law Wire.
324 articles
Also before the court
- FDA Hits Caplin Steriles Plant With OAI Status After 10 Observations
- CCPA Fines Just Dial ₹10 Lakh Over Ammonium Nitrate Listings
- Waaree Energies Acknowledges Solar Import Origin Errors
- US Anti-Dumping Duties of Up to 123% Target Indian Solar Imports
- Maharashtra Forest Department Halts Adani's 1,500 MW Tarali Hydro Project